HCA Healthcare, Inc.

NYSE:HCA Stock Report

Market Cap: US$96.7b

HCA Healthcare Valuation

Is HCA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of HCA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: HCA ($445.77) is trading below our estimate of future cash flow value ($869.77)

Significantly Below Future Cash Flow Value: HCA is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HCA?

Key metric: As HCA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HCA. This is calculated by dividing HCA's market cap by their current earnings.
What is HCA's PE Ratio?
PE Ratio14.2x
EarningsUS$6.79b
Market CapUS$96.68b

Price to Earnings Ratio vs Peers

How does HCA's PE Ratio compare to its peers?

The above table shows the PE ratio for HCA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.2x
THC Tenet Healthcare
11.6x-2.32%US$15.8b
UHS Universal Health Services
7.4x0.44%US$10.6b
EHC Encompass Health
17.7x10.06%US$10.1b
ENSG Ensign Group
32.3x13.22%US$11.0b
HCA HCA Healthcare
14.7x4.04%US$96.7b

Price-To-Earnings vs Peers: HCA is good value based on its Price-To-Earnings Ratio (14.7x) compared to the peer average (17.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does HCA's PE Ratio compare vs other companies in the US Healthcare Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
0.8x-109.85%US$368.43m
IDXG Interpace Biosciences
2.1xn/aUS$54.71m
RHEP Regional Health Properties
1.7xn/aUS$5.25m
NIVF NewGenIvf Group
0.1xn/aUS$1.11m
HCA 14.2xIndustry Avg. 24.3xNo. of Companies11PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HCA is good value based on its Price-To-Earnings Ratio (14.7x) compared to the US Healthcare industry average (24.3x).

Price to Earnings Ratio vs Fair Ratio

What is HCA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HCA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.2x
Fair PE Ratio29.8x

Price-To-Earnings vs Fair Ratio: HCA is good value based on its Price-To-Earnings Ratio (14.7x) compared to the estimated Fair Price-To-Earnings Ratio (29.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HCA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$445.77
US$515.24
+15.58%
10.31%US$635.00US$396.00n/a21
Apr ’27US$474.75
US$543.05
+14.39%
9.45%US$635.00US$425.00n/a21
Mar ’27US$529.70
US$541.52
+2.23%
9.47%US$635.00US$425.00n/a21
Feb ’27US$488.27
US$528.52
+8.24%
9.94%US$598.00US$420.00n/a21
Jan ’27US$466.86
US$481.95
+3.23%
8.76%US$525.00US$368.00n/a20
Dec ’26US$503.00
US$477.70
-5.03%
8.75%US$525.00US$368.00n/a20
Nov ’26US$459.68
US$474.29
+3.18%
9.78%US$525.00US$368.00n/a21
Oct ’26US$426.07
US$403.81
-5.22%
7.87%US$449.00US$333.00n/a21
Sep ’26US$403.96
US$396.29
-1.90%
7.10%US$444.00US$333.00n/a21
Aug ’26US$356.97
US$393.62
+10.27%
7.00%US$444.00US$333.00n/a21
Jul ’26US$389.53
US$387.75
-0.46%
9.18%US$444.00US$316.00n/a22
Jun ’26US$381.39
US$380.34
-0.28%
9.00%US$444.00US$316.00n/a22
May ’26US$343.04
US$371.84
+8.40%
9.14%US$438.00US$316.00n/a22
Apr ’26US$345.73
US$374.89
+8.43%
9.37%US$438.00US$316.00US$474.7523
Mar ’26US$306.30
US$374.89
+22.39%
9.37%US$438.00US$316.00US$529.7023
Feb ’26US$329.91
US$377.15
+14.32%
9.28%US$438.00US$316.00US$488.2723
Jan ’26US$300.15
US$398.84
+32.88%
9.95%US$460.00US$316.00US$466.8623
Dec ’25US$327.22
US$404.19
+23.52%
8.76%US$460.00US$316.00US$503.0023
Nov ’25US$357.19
US$407.10
+13.97%
7.65%US$460.00US$316.00US$459.6824
Oct ’25US$405.45
US$396.60
-2.18%
7.55%US$455.00US$316.00US$426.0724
Sep ’25US$395.59
US$389.58
-1.52%
6.46%US$438.00US$316.00US$403.9623
Aug ’25US$363.12
US$380.27
+4.72%
5.80%US$410.00US$316.00US$356.9723
Jul ’25US$315.12
US$353.07
+12.04%
7.72%US$397.00US$285.00US$389.5323
Jun ’25US$339.75
US$348.68
+2.63%
7.02%US$396.00US$285.00US$381.3923
May ’25US$309.44
US$343.58
+11.03%
6.75%US$378.00US$285.00US$343.0423
Apr ’25US$330.11
US$337.54
+2.25%
6.06%US$378.00US$285.00US$345.7323
US$515.24
Fair Value
13.5% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/27 18:12
End of Day Share Price 2026/04/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HCA Healthcare, Inc. is covered by 39 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Hua HaBaird
Adam FeinsteinBarclays